Regenerative Medicine Industry Optimistic, But May Need Payment Tweaks

The leading regenerative medicine trade association is optimistic that the field will continue to rapidly advance in 2018 buoyed by FDA’s rapid acceptance of the field and the deep pipeline of products in development. While 2018 may bring approval of only a handful of products, much like 2017, the association expects that a wave of products will likely come to market in subsequent years. However, the high prices of these products, which supporters chalk up to the fact that the...